Reportstack

Affectis Pharmaceuticals AG - Product Pipeline Review - 2012 New Report

 

Naperville, IL -- (SBWIRE) -- 10/09/2012 -- Affectis Pharmaceuticals AG - Product Pipeline Review - 2012 provides data on the Affectis Pharmaceuticals AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Affectis Pharmaceuticals AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Affectis Pharmaceuticals AG and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Affectis Pharmaceuticals AG - Brief Affectis Pharmaceuticals AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Affectis Pharmaceuticals AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Affectis Pharmaceuticals AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Affectis Pharmaceuticals AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Affectis Pharmaceuticals AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Affectis Pharmaceuticals AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Affectis Pharmaceuticals AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Affectis Pharmaceuticals AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Affectis Pharmaceuticals AG and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Affectis Pharmaceuticals AG; Affectis Pharmaceuticals AG - Key Therapeutics; Affectis Pharmaceuticals AG - Pipeline Overview and Promising Molecules; Affectis Pharmaceuticals AG - News; Affectis Pharmaceuticals AG - Latest Updates; Affectis Pharmaceuticals AG - Pipeline; Affectis Pharmaceuticals AG - Discontinued/Dormant Projects

To view table of contents for this market report please visit:
http://www.reportstack.com/product/85332/affectis-pharmaceuticals-ag-product-pipeline-review-2012.html